Amarin Corporation (AMRN) Q4 2024 earnings summary

Executive summary

• Achieved 2024 revenues of $228.6 million, ending with $294.2 million in cash and no debt, reflecting a strong financial position and operational streamlining.

• Expanded Vascepa/VAZKEPA's global reach, now approved in 49 markets, launched in over 20, and advanced commercialization in 16 more countries, including launches in Italy, China, and Australia.

• Announced a 1-for-20 ADS ratio change to maintain Nasdaq listing and preserve access to equity capital markets, effective around April 11, 2025.

• Extended European IP protection for Vascepa to 2039, supporting long-term exclusivity.

Financial highlights

• Q4 2024 net revenue was $62.3 million, down 17% year-over-year, mainly due to U.S. generic competition and CVS coverage changes.

• U.S. product revenue was $44.2 million (Q4 2024) vs. $64.9 million (Q4 2023); European revenue grew to $4 million, up from $1.5 million; Rest of World partnerships generated $11.9 million, up from $4.2 million.

• Gross margin (excluding non-cash inventory restructuring) was 41% in Q4 2024 versus 58% prior year.

• Q4 2024 GAAP net loss was $48.6 million, compared to $5.8 million loss in Q4 2023, mainly due to non-cash inventory restructuring.

• Operating expenses for Q4 were $43 million, down 18% year-over-year due to cost optimization.

Outlook and guidance

• Focused on maintaining Nasdaq listing, driving European and global expansion, and maximizing U.S. profitability.

• Anticipates continued U.S. revenue pressure in H1 2025 due to ongoing generic competition and CVS coverage changes.

• Prioritizing efficient cash management and value-driven investments, with a long cash runway and no debt.

• Exploring business development opportunities, primarily in cardiovascular and cardiometabolic areas, but main focus remains on Vascepa execution.

• Current cash and assets are considered sufficient to support ongoing operations for the foreseeable future.